These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 22605725

  • 1. AIDS research. FDA panel recommends anti-HIV drug for prevention.
    Cohen J.
    Science; 2012 May 18; 336(6083):792. PubMed ID: 22605725
    [No Abstract] [Full Text] [Related]

  • 2. HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.
    Cohen J.
    Science; 2010 Dec 03; 330(6009):1298-9. PubMed ID: 21127220
    [No Abstract] [Full Text] [Related]

  • 3. FDA approves first drug to prevent HIV infection.
    Roehr B.
    BMJ; 2012 Jul 17; 345():e4879. PubMed ID: 22807165
    [No Abstract] [Full Text] [Related]

  • 4. HIV pre-exposure prophylaxis.
    Morin SF, Yamey G, Rutherford GW.
    BMJ; 2012 Aug 13; 345():e5412. PubMed ID: 22890030
    [No Abstract] [Full Text] [Related]

  • 5. Transmission. Company halts Truvada PrEP for women study.
    AIDS Policy Law; 2011 Jun 13; 26(7):1. PubMed ID: 21735622
    [No Abstract] [Full Text] [Related]

  • 6. Generic Truvada approved.
    AIDS Patient Care STDS; 2009 May 13; 23(5):395. PubMed ID: 19422066
    [No Abstract] [Full Text] [Related]

  • 7. Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.
    Blackwell CW.
    Nurse Pract; 2014 Sep 18; 39(9):50-3. PubMed ID: 25140852
    [Abstract] [Full Text] [Related]

  • 8. AIDS research. Complexity surrounds HIV prevention advances.
    Cohen J.
    Science; 2011 Jul 22; 333(6041):393. PubMed ID: 21778370
    [No Abstract] [Full Text] [Related]

  • 9. FDA PrEPares to reduce risk of HIV infection with Truvada®.
    Breeze S.
    Expert Rev Clin Pharmacol; 2012 Sep 22; 5(5):499. PubMed ID: 23272332
    [No Abstract] [Full Text] [Related]

  • 10. HIV prevention trial in women is abandoned after drugs show no impact on infection rates.
    Roehr B.
    BMJ; 2011 Apr 20; 342():d2613. PubMed ID: 21508055
    [No Abstract] [Full Text] [Related]

  • 11. FDA treads carefully with PrEP.
    Holmes D.
    Lancet Infect Dis; 2012 Jul 20; 12(7):515-6. PubMed ID: 22930826
    [No Abstract] [Full Text] [Related]

  • 12. Early end for FEM-PrEP HIV prevention trial.
    AIDS Patient Care STDS; 2011 Jun 20; 25(6):383. PubMed ID: 21612547
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HIV/AIDS. ARVs as HIV prevention: a tough road to wide impact.
    Shelton JD.
    Science; 2011 Dec 23; 334(6063):1645-6. PubMed ID: 22194560
    [No Abstract] [Full Text] [Related]

  • 15. Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.
    Coutinho B, Prasad R.
    Am Fam Physician; 2013 Oct 15; 88(8):535-40. PubMed ID: 24364575
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FDA approves Viread for HIV-1 infection.
    FDA Consum; 2002 Oct 15; 36(1):5. PubMed ID: 11881601
    [No Abstract] [Full Text] [Related]

  • 18. FDA must publish data on safety and efficacy of prophylactic AIDS drug, court rules.
    Hawkes N.
    BMJ; 2013 Aug 19; 347():f5161. PubMed ID: 23959292
    [No Abstract] [Full Text] [Related]

  • 19. Viread gets FDA nod.
    Rodriquez E.
    Posit Living; 2013 Aug 19; 10(7):33. PubMed ID: 11808509
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.